A Clinical Investigation of the Mechanism of Loxoprofen, a Non-steroidal Anti-inflammatory Drug, for Patients with Nocturia

被引:0
|
作者
Araki, Tohru [2 ]
Yokoyama, Teruhiko [1 ]
Araki, Motoo [3 ]
Furuya, Seiji [4 ]
机构
[1] Kawasaki Med Sch, Dept Urol, Okayama 7010192, Japan
[2] Araki Urol Clin, Okayama 7100834, Japan
[3] Okayama Univ, Dept Urol, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008558, Japan
[4] Furuya Hosp, Kitami, Hokkaido 0900065, Japan
关键词
loxoprofen; nocturia; NSAID;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We previously reported the effectiveness of loxoprofen sodium (loxoprofen), a non-steroidal anti-inflammatory drug, for patients with lower urinary tract symptoms (LUTS) complaining of nocturia. In this study, we explored the mechanism of loxoprofen in the treatment of nocturia. Fifty-six patients complaining of nocturia were enrolled. They took a single 60-mg tablet of loxoprofen at bedtime for 14 days. The effects of this treatment were assessed by bladder diaries. Nocturia improved (nocturia decreased >= 1 void/night) in 40 patients (71.4%). Nocturnal urine volume was reduced in 31 of 40 (77.5%) without nocturnal single-void volume increase. Nocturnal single-void volume increased in 4 of 40 (10.0%) without nocturnal urine volume reduction. Two of 40 (5.0%) demonstrated both nocturnal urine volume reduction and nocturnal single-void volume increase. Three (7.5%) were exceptions to the above. In conclusion, the main mechanism of loxoprofen is the reduction of nocturnal urine volume for the treatment of nocturia and the second mechanism is the increased bladder capacity.
引用
收藏
页码:373 / 378
页数:6
相关论文
共 50 条
  • [21] Intravenous self-administration of benzydamine, a non-steroidal anti-inflammatory drug with a central cannabinoidergic mechanism of action
    Avvisati, Riccardo
    Meringolo, Maria
    Stendardo, Emiliana
    Malavasi, Elisa
    Marinelli, Silvia
    Badiani, Aldo
    ADDICTION BIOLOGY, 2018, 23 (02) : 610 - 619
  • [22] Underutilization of gastroprotective drugs in patients receiving non-steroidal anti-inflammatory drugs
    Thiefin, Gerard
    Schwalm, Marie-Sophie
    DIGESTIVE AND LIVER DISEASE, 2011, 43 (03) : 209 - 214
  • [23] A fatal case of bowel obstruction caused by non-steroidal anti-inflammatory drug enteropathy
    Huddleston, William Ryan
    Johnson, Christopher
    FORENSIC SCIENCE MEDICINE AND PATHOLOGY, 2019, 15 (03) : 502 - 505
  • [24] Non-steroidal anti-inflammatory drugs in colic-therapy
    Wogatzki, Anna
    PFERDEHEILKUNDE, 2016, 32 (05): : 508 - 514
  • [26] Biological rhythms, inflammation and non-steroidal anti-inflammatory agents
    Bureau, JP
    Labrecque, G
    PATHOLOGIE BIOLOGIE, 1996, 44 (07): : 610 - 617
  • [27] Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk
    Hermann, M
    Ruschitzka, F
    INTERNAL MEDICINE JOURNAL, 2006, 36 (05) : 308 - U5
  • [28] Incorporating the Non-steroidal Anti-inflammatory Drug Meloxicam into the Treatment of Clinical Mastitis Reduced SCC and the Risk of Culling
    Bryan, M. A.
    McDougall, S.
    Tiddy, R. M.
    CATTLE PRACTICE, 2009, 17 : 173 - 183
  • [29] Capillary electrophoresis for the analysis of non-steroidal anti-inflammatory drugs
    Macia, Alba
    Borrull, Francesc
    Calull, Marta
    Aguilar, Carme
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2007, 26 (02) : 133 - 153
  • [30] Oral drug challenges in non-steroidal anti-inflammatory drug-induced urticaria, angioedema and anaphylaxis
    Chaudhry, T.
    Hissaria, P.
    Wiese, M.
    Heddle, R.
    Kette, F.
    Smith, W. B.
    INTERNAL MEDICINE JOURNAL, 2012, 42 (06) : 665 - 671